Grigory Horonenko, DO
Pulmonary Disease · Phoenix, AZNPI 1356394035
Payments from drug & device makers
Across 574 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Electromed, Inc.$973
- Actelion Pharmaceuticals US, Inc.$963
- GSK$944
- Insmed, Inc.$899
- Boehringer Ingelheim$862
- plus $5K from 32 others
What the payments were for
- Food & beverage$10,98297%
- Education$3613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,366 |
| Electromed, Inc. | 96 | $973 |
| Actelion Pharmaceuticals US, Inc. | 36 | $963 |
| GSK | 64 | $944 |
| Insmed, Inc. | 40 | $899 |
| Boehringer Ingelheim | 35 | $862 |
| Regeneron Healthcare Solutions, Inc. | 20 | $591 |
| Genentech USA, Inc. | 30 | $564 |
| Sanofi | 25 | $493 |
| United Therapeutics Corporation | 22 | $477 |
| Abiomed | 3 | $456 |
| Baxter Healthcare | 16 | $314 |
| AbbVie(2 entities) | 13 | $289 |
| Philips North America LLC | 12 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $225 |
| Mylan Specialty L.p. | 11 | $198 |
| Merck | 5 | $191 |
| Amgen | 8 | $183 |
| Advanced Respiratory, Inc | 16 | $170 |
| Grifols USA, LLC | 6 | $144 |
| Sunovion Pharmaceuticals Inc. | 8 | $130 |
| Sandoz | 4 | $98 |
| Novartis | 4 | $93 |
| Teva Pharmaceuticals USA, Inc. | 5 | $87 |
| Verona Pharma, Inc. | 2 | $58 |
| Getinge USA Sales, LLC | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| Gilead | 2 | $32 |
| Inogen, Inc. | 2 | $24 |
| Bayer | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Abbott | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Pulmonx Corporation | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,342 in reported general payments places this provider in the 70th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $311,639 |
| OpsumitMacitentan | 13 | $166,709 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 193 | $154,264 |
| Ambrisentan | 25 | $114,594 |
| TezspireTezepelumab-Ekko | 13 | $59,917 |
| Dupixent PenDupilumab | 14 | $53,522 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $34,369 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $33,063 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $31,823 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $29,990 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $11,615 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,020 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $5,844 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 192 | $5,285 |
| Sildenafil Citrate | 17 | $3,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $862 | $355,02872 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $944 | $217,317306 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $963 | $166,70913 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,366 | $103,35589 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Mark GotfriedPhoenix$1.1M
- Abid KhokarPhoenix$321K
- Brian PorvinPhoenix$276K
- Tony HodgesPhoenix$262K
- Rajeev SaggarPhoenix$219K
- Ali SaeedPhoenix$213K
- Bhuvin BuddhdevPhoenix$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.